Posted by Michael Wonder on 30 Jun 2020
Nordic Nanovector's Betalutin receives fast track designation from US FDA for marginal zone lymphoma
29 June 2020 - Nordic Nanovector today announces that the US FDA has granted fast track designation for investigating Betalutin (177Lu lilotomab satetraxetan) for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least two prior systemic therapies.
Nordic Nanovector is evaluating the opportunity to develop Betalutin as a single-agent treatment for marginal zone lymphoma, a rare type of non-Hodgkin's lymphoma.
Betalutin has demonstrated a very promising clinical effect in nine marginal zone lymphoma patients in the Phase 1/2a LYMRIT 37-01 trial.
